News Releases

The Penn Medicine Princeton Cancer Center received a $2.5 million grant from the Bristol Myers Squibb Foundation to help fund an innovative program to ensure holistic, patient-centered care for older adults with cancer.

Simultaneously knocking out two inflammatory regulators offers a “one-two punch” to enhance T cell potency, according to a new preclinical study. The approach demonstrates promise to improve T cell therapy in solid tumors.

Electronic nudges delivered to health care clinicians based on a machine learning algorithm quadrupled rates of conversations with patients about their care preferences and significantly decreased use of aggressive chemotherapy at end of life.

CAR T cell therapy, an approach which reprograms patients’ own immune cells to attack their blood cancers, may enhance the effectiveness surgery for of solid tumors, according to a new preclinical study.

A first-of-its-kind drug known as modakafusp alfa has shown early potential in combating multiple myeloma, a form of bone marrow cancer, in a study presented at the 2022 ASH Annual Meeting by Penn Medicine.

Penn Medicine researchers presented preliminary results from an ongoing clinical trial demonstrating successful re-treatment with CAR T cell therapy at the 2022 ASH Annual Meeting.

A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, a Penn Medicine study found.

Penn Medicine researchers laud early results for CAR T therapy in a small set of patients with the autoimmune disease lupus.